Cellectis SA. Daily Stock Analysis

Daily Stock Analysis, CLLS, Cellectis SA, priceseries

Cellectis SA. Daily Stock Analysis
Stock Information
Open
3.62
Close
3.45
High
3.65
Low
3.43
Previous Close
3.53
Daily Price Gain
-0.08
YTD High
8.82
YTD High Date
Jan 3, 2022
YTD Low
3.43
YTD Low Date
Mar 7, 2022
YTD Price Change
-5.32
YTD Gain
-60.66%
52 Week High
24.02
52 Week High Date
Mar 16, 2021
52 Week Low
3.43
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-14.83
52 Week Gain
-81.13%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
18.24
Feb 23. 2017
21.56
16 Trading Days
18.20%
Link
LONG
Aug 22. 2017
24.23
Sep 5. 2017
26.42
9 Trading Days
9.04%
Link
LONG
Apr 1. 2019
18.57
Apr 24. 2019
19.96
16 Trading Days
7.48%
Link
LONG
Oct 25. 2019
10.86
Nov 20. 2019
12.91
18 Trading Days
18.92%
Link
LONG
Nov 21. 2019
13.29
Dec 30. 2019
17.42
25 Trading Days
31.10%
Link
LONG
Apr 6. 2020
8.85
Apr 24. 2020
12.07
13 Trading Days
36.41%
Link
LONG
Sep 11. 2020
17.45
Sep 22. 2020
18.89
7 Trading Days
8.23%
Link
LONG
Nov 11. 2020
17.61
Dec 10. 2020
26.63
20 Trading Days
51.21%
Link
Company Information
Stock Symbol
CLLS
Exchange
NasdaqGM
Company URL
http://www.cellectis.com
Company Phone
33181691600
CEO
André Choulika
Headquarters
-
Business Address
8 RUE DE LA CROIX JARRY, PARIS, LLE-DE-FRANCE, FRANCE 75013
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001627281
About

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Description

Developing cancer immunotherapies based on gene-edited CAR T-cells.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading